Top

Published in:

Open Access 01-12-2014 | Poster presentation

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

Authors: R Millican-Slater, D Dodwell, K Horgan, M Mcmahon, B Dall, N Sharma

Published in: Breast Cancer Research | Special Issue 1/2014

Excerpt

There are few data regarding the effect of neoadjuvant chemotherapy (NACT) and trastuzumab on any ductal carcinoma in situ (DCIS) associated with the HER2-positive invasive carcinoma. HER2-positive breast cancers are more likely to achieve a pathological complete response (defined as absence of invasive tumour in the final excision specimen allowing for the presence of DCIS). We review our data to see what happens to HER2-positive DCIS associated with HER2-positive invasive cancer treated with NACT. …

Title: PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?
Authors: R Millican-Slater
D Dodwell
K Horgan
M Mcmahon
B Dall
N Sharma
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue Special Issue 1/2014
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr3735

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2014

PB.11. Modern management of acute breast abscesses: radiological interventions replacing surgical incisions?

PB.44. Do qualitative patterns of stiffness help differentiate benign from malignant breast masses of similar stiffness during shear wave elastography?

PB.8. Ultrasound-guided excision of fibroadenomas: 9 years' experience in a British breast unit

PB.45. Correlation of perilesional tissue stiffness measured by ultrasound strain elastography with breast density

PB.13. Impact on film reading of moving from analogue to digital screening: a service evaluation - South East Scotland Breast Screening Programme

PB.12. Audit and root-cause analysis of classification 2 and 3 interval cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer